Global Blood Therapeutics, Inc. (GBT)

$67.99

+0.02 (+0.03%)
Rating:
Recommendation:
Neutral
Symbol GBT
Price $67.99
Beta 0.463
Volume Avg. 3.42M
Market Cap 4.588B
Shares () -
52 Week Range 21.65-73.02
1y Target Est -
DCF Unlevered GBT DCF ->
DCF Levered GBT LDCF ->
ROE -170.37% Strong Sell
ROA -37.05% Strong Sell
Operating Margin -
Debt / Equity 635.42% Strong Buy
P/E -
P/B 37.68 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GBT news


Dr. Ted Love
Healthcare
Biotechnology
NASDAQ Global Select

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.